2069results about "Antimycotics" patented technology

The invention discloses hydrogel loaded with antibacterial polypeptide as well as a preparation method and application of the hydrogel. The preparation method of the hydrogel comprises the steps that antibacterial polypeptide and polyethylene glycol dimethacrylate are subjected to a cross-linking reaction, the hydrogel can be obtained, and the antibacterial polypeptide is obtained through polymerization synthesis of a cationic CBL monomer compound and an HBL monomer compound; the hydrogel has remarkable sterilization and anti-biofilm effects, and in-vitro cytotoxicity shows that the antibacterial polypeptide hydrogel product has no inhibition effect on normal cell growth; when the hydrogel dressing is used as a hydrogel dressing and is combined with novobiocin for use, more than 99% of antibacterial effect is achieved in a diabetes wound infection model and a fungal psoriasis infection model; and when being used as a hydrogel preparation to be combined with fluconazole, the compound has the effect of inhibiting growth of more than 99% of fungi in an animal vaginitis model.

Provided is an antibacterial peptide having an amino acid sequence X1KRFKKFFX2KLKKWV-NH2, wherein X1 is selected from any one or of amino acids A, C, D, E, F, G, H, K, L, N, M, P, Q, R, S, I, V, W, Y, and T or is absent; and X2 is an amino acid having an aromatic side chain or an amino acid having an alkaline side chain. In view of defects such as poor gastrointestinal fluid stability of antibacterial peptides in the prior art, a brand-new sequence design scheme and preparation method for an antibacterial peptide are provided. By means of a complete or partial D-amino acid substitution or structural derivatization of a peptide sequence, a series of antimicrobial peptides having stronger antibacterial activity and gastrointestinal stability as compared with the prior art are obtained, such that the antibacterial peptides have a wider application range and higher development potential value.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention discloses a dual-mechanism antibacterial photosensitizer as well as a preparation method and application thereof, and relates to the technical field of biomedical photoelectric functional materials. The invention relates to a triphenylamine derivative, which can realize fluorescence imaging of bacterial or fungal infection by utilizing fluorescence characteristics, can generate active oxygen under illumination to play a photodynamic therapy role, is suitable for preparing photodynamic therapy preparations and developing antibacterial materials, and can also be applied to the fields of environment and public health and tumor treatment. The problems that an existing photosensitizer is insufficient in broad spectrum, different in fungus drug resistance mechanism, limited in single treatment effect and the like can be effectively solved, and the photosensitizer has wide application prospects.

The present disclosure relates generally to antimicrobial gels. In particular, the present disclosure relates to an antimicrobial gel comprising a eutectic solvent and a gelling agent which can be used as a drug delivery vehicle for antimicrobial agents, including for the topical delivery of antimicrobial agents to the skin of a subject. The present disclosure also relates to processes for preparing the antimicrobial gel, and to methods, uses and compositions comprising the antimicrobial gel.

The invention discloses an eel antibacterial polypeptide Ajaspkidin and application thereof in preparation of an anti-vibrio composition. The amino acid sequence of the eel antibacterial polypeptide Ajaspkidin is shown as SEQ ID NO.01. The invention further discloses an application of the eel antibacterial polypeptide The zebra fish antibacterial peptide has the characteristics of excellent molecular characteristics, broad-spectrum antibacterial activity, efficient bactericidal ability, high thermal stability, high biological safety, anti-infection effect on zebra fish infected by vibrio vulnificus, capability of remarkably improving the survival rate of bred animals and the like, and has a wide application prospect.

The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.

The invention relates to the technical field of antibacterial drugs, in particular to an antibacterial peptide which has an amino acid sequence X1KRFKKFFX2KLKKWV-NH2, in which X1 is selected from any one or deletion of amino acids A, C, D, E, F, G, H, K, L, N, M, P, Q, R, S, I, V, W, Y and T; and X2 represents an amino acid having an aromatic side chain or an amino acid having a basic side chain. Aiming at the defects of poor gastrointestinal fluid stability and the like of the antibacterial peptide in the prior art, the invention provides a brand new antibacterial peptide sequence design scheme and a preparation method thereof, and the peptide sequence is subjected to full D-type amino acid or partial D-type amino acid replacement or structure derivation; compared with the prior art, a series of antibacterial peptides with higher antibacterial activity and gastrointestinal fluid stability are obtained, so that the antibacterial peptides have wider application range and higher potential development value.

The invention discloses a bacillus strain H7 and an application thereof. The invention provides bacillus velezensis H7 or a progeny of the bacillus velezensis H7, and the preservation number of the bacillus velezensis H7 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 2025630. The bacillus velezensis H7 disclosed by the invention has a very good antibacterial effect on various common clinical pathogenic bacteria (including klebsiella pneumoniae, escherichia coli, candida albicans, enterobacter cloacae complex, acinetobacter baumannii and the like), and particularly shows a very high inhibition rate on some drug-resistant clinical pathogenic bacteria; therefore, the compound has important application value in development of drug and non-drug antibacterial products (such as medical antibacterial materials and the like), a new choice can be provided for drug and non-drug prevention and control of clinical pathogenic bacterium infection, and particularly, the compound has a supplementary effect in the aspects of reducing drug-resistant bacterium propagation risk and reducing drug dependence.

The invention discloses application of tannic acid combined triazole medicines in preparation of medicines for treating diseases caused by fungi, and belongs to the technical field of antifungal. A series of drug sensitive tests show that tannic acid lower than 3 [mu] g / ml has no influence on the activity of human vaginal epithelial cells, and after the tannic acid is combined with fluconazole, the tannic acid can significantly inhibit the growth activity of drug-resistant candida (including drug-resistant candida albicans and drug-resistant candida glabrata). In view of the natural property, wide source and low toxicity of tannic acid, the invention provides a new antifungal treatment strategy, and the tannic acid has important clinical application value for treating infection (such as vaginal candidiasis) caused by drug-resistant fungi, especially under the condition that the existing antifungal drugs are poor in effect. Therefore, the tannic acid combined triazole medicine can be used for preparing the medicine for treating diseases caused by fungi.

The present disclosure relates to compositions and methods comprising a yeast cell wall extract and a clay material admixed to a proteinaceous and / or cell wall extract(s) from bacterial or fungal fermentation from amino acid production. In another embodiment, the present compositions comprise a yeast cell wall extract, a clay material, and an algal material admixed to a proteinaceous and / or cell wall extract(s) from bacterial or fungal fermentation from amino acid production. This disclosure also relates to methods of utilizing the same to sequester and / or adsorb mycotoxins internal or external to an animal, thereby reducing and / or preventing the toxic and harmful effects of mycotoxin contamination and / or infection in animals. Specifically, application of the present methods and compositions are found in the dietary administration and / or co-administration of the present compositions to animals in animal feed and / or animal production systems, as well as in therapeutic, prophylactic, and research applications.

The invention discloses a composition for improving the stability of oleuropein in a solution as well as a preparation method and application of the composition. The composition comprises oleuropein and at least one stabilizer, and the stabilizer is selected from the group consisting of anisic acid, lactobionic acid, glycyrrhizic acid, 3, 3-thiodipropionic acid, N-acetyl-L-glutamine, propyl-cysteine and lauramidopropyl betaine; and the pH value of the aqueous solution of the composition is 4.0-8.0. The preparation method comprises the following steps: dissolving oleuropein in water, adding the stabilizer, and uniformly mixing. Through simple physical mixing, by utilizing the synergistic effect of the specific stabilizer and the oleuropein, the degradation and discoloration of the oleuropein in the storage process are remarkably inhibited. Experiments show that after the preferable composition is preserved for 30 days in an open manner, the retention rate of the oleuropein still reaches up to 80% or above, and is far superior to that of blank control and a traditional liposome wrapping method. The composition is simple and convenient in preparation process and low in cost, and provides reliable technical support for wide application of oleuropein in liquid products such as food, medicine and cosmetics.

The invention relates to plant lactobacillus and application thereof. Wherein the gene of the molecular marker for the plant lactobacillus has a nucleotide sequence selected from one of the following sequences: (1) a nucleotide sequence as shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99% or higher homology with the nucleotide sequence as shown in SEQ ID NO: 24; and (3) a nucleotide sequence with one or more nucleotide sequences, such as 1, 2, 3, 4, 5 or more nucleotide substitutions, deletion or insertion, in the nucleotide sequence as shown in SEQ ID NO: 24. The plant lactobacillus provided by the invention is non-toxic, has good biological characteristics, has a good curative effect on prevention and / or treatment of vaginal infection and related diseases, and avoids the problems of increased drug resistance, high recurrence rate and the like caused by use of antibiotic and other antibacterial drugs during treatment of vaginal infection and related diseases.

The invention discloses an antibacterial peptide as well as a preparation method and application thereof. The antibacterial peptide has an amino acid sequence as shown in any one of SEQ ID NO: 1-11. The antibacterial peptide prepared by the scheme provided by the invention has very strong bacteriostasis and sterilization capabilities on methicillin-resistant staphylococcus aureus and multidrug-resistant escherichia coli, has application potential of becoming an antibacterial agent, a preservative or a disinfectant, and is not easy to generate drug resistance.

The invention discloses an AIE imitated antibacterial peptide material and a preparation method and application thereof, and belongs to the technical field of polymer materials, the AIE imitated antibacterial peptide material takes an alkyl chain as a main chain, the position of a cation primitive is regulated, and AIE primitives with different D-A structures are combined as side chains, so that the AIE imitated antibacterial peptide material is prepared. Through the D-A structure in the AIE element, the molecular can be used for the performance regulation and control of generating ROS or photo-thermal through illumination response, so that the growth and proliferation of microorganisms can be inhibited, and the damage to a biofilm is further inhibited. The AIE imitated antibacterial peptide material is good in biocompatibility and has a wide application prospect in the field of antibacterial agents.

The invention discloses a preparation process of a pure plant essential oil disinfectant, and relates to the technical field of disinfectants. The problems that plant essential oil is poor in solubility in a water phase, low in stability and the like are solved. The method specifically comprises the following steps: preparing raw materials; preparing a nano emulsion; preparing a solvent and mixing; constructing a natural stable system to obtain a primary product; filtering and sterilizing; and carrying out sterile filling on the disinfectant finished product. The invention provides a pure plant essential oil disinfectant prepared by dissolving type 1 and 8 melaleuca alternifolia essential oil in water, efficient dispersion is realized through a nano-emulsification and natural stabilization technology so as to form a stable aqueous solution, an amphiphilic structure of soapbark saponin is utilized, aglycone and essential oil terpene form a supramolecular compound, and the stable aqueous solution can be used for sterilizing the melaleuca alternifolia essential oil and the melaleuca alternifolia essential oil and the melaleuca alternifolia essential oil. The technical problems of poor dissolvability and low stability of plant essential oil in a water phase are solved, and the plant essential oil has broad-spectrum antibacterial and antiviral characteristics and can meet the disinfection requirements in multiple fields such as medical treatment, object surface treatment, home furnishing and personal care.

The invention discloses a compound as shown in a formula (I), and / or pharmaceutically acceptable salts thereof, and / or a raceme mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and belongs to the technical field of medicines. The invention also discloses a pharmaceutical composition containing the compound as shown in the formula (I), and the compound as shown in the formula (I) and / or a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and / or the pharmaceutical composition, a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof. The invention further discloses application of the cGAS agonist in preparation of the cGAS agonist and a medicament for treating diseases responding to activation of the cGAS-STING signal channel.

The invention discloses an anguilla anguilla antibacterial peptide Anguinin and application thereof. The amino acid sequence of the anguilla anguilla antibacterial peptide Anguinin is shown as SEQ ID NO. 01. The amino acid sequence consists of 18 amino acid residues, and the molecular weight of the amino acid sequence is 2091.41 Daltons. According to the prediction of a HeliQuest tool, the net charge number is + 5, the hydrophobicity value is 0.267, and meanwhile, good water solubility is shown. As a typical cationic polypeptide with positive charges, the cationic polypeptide has the remarkable advantages of being easy to chemically synthesize, wide in antibacterial spectrum, efficient in antibacterial activity, high in safety and the like, a solid foundation is laid for practical application of the cationic polypeptide in the fields of pharmacy and feed addition due to the characteristics, and wide commercialization prospects are shown.

The invention relates to the technical field of medicines, in particular to application of tedizolid combined with fluconazole in preparation of antifungal drugs. The tedizolid and the fluconazole are combined for use, so that the antibacterial activity of the fluconazole on the candida albicans can be enhanced, a synergistic antifungal effect can be generated, and the drug resistance of the candida albicans on the fluconazole can be reversed.

The present invention discloses a sea dragon-derived antimicrobial peptide, SsPle, for antimicrobial applications in the complex environments of tropical islands and reefs. The amino acid sequence of this antimicrobial peptide is shown in SEQ ID NO. 3. This antimicrobial peptide, SsPle, exhibits good water solubility, broad antimicrobial activity, and highly stable antimicrobial properties under high temperature, high salt, and ultraviolet irradiation conditions. It can inhibit the release of free bacterial endotoxins and has significant application prospects as an eco-friendly antimicrobial agent in the unique environments of South China Sea islands and reefs.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bleomycin or bleomycin analogues in preparation of an immunopotentiator. The invention also provides a pharmaceutical composition and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing cancers. The pharmaceutical composition comprises bleomycin, bleomycin analogues or a combination thereof and an anti-tumor immunotherapeutic agent.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The invention relates to the field of microorganisms, in particular to lactobacillus plantarum TRT-01 with anti-inflammatory and bacteriostatic functions as well as a preparation method and application of the lactobacillus plantarum TRT-01, the lactobacillus plantarum TRT-01 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32237, and the preservation date is October 17, 2024. The plant lactobacillus has broad-spectrum bacteriostatic activity on 10 pathogenic bacteria such as helicobacter pylori, streptococcus mutans and the like, and can regulate Th1 / Treg immune balance and relieve inflammatory response by inducing dendritic cells to secrete cell factors IL-10 and IL-12, inducing T cells to secrete cell factors TGF-beta and IFN-gamma and inhibiting secretion of cell factors IL-6 at the same time. Therefore, the plant lactobacillus TRT-01 disclosed by the invention can be used for preparing a composition with anti-inflammatory and bacteriostatic effects, is suitable for the fields of medicines, foods, health-care products and the like, and is particularly suitable for developing a microbial preparation with a probiotic effect.

To provide an amine of a specific compound, a carbonic acid adduct and a pharmaceutical composition for use in the treatment of atypical pneumonia and in the therapy of viral diseases.SOLUTION: The present invention provides an amine (AM) of the general formula (I) for use in the treatment of atypical pneumonia and in the therapy of viral diseases.SELECTED DRAWING: None

The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.

The invention relates to the technical field of biological medicine, in particular to application of a combination of a Cd1 and Mdr1 double-target inhibitor and an azole drug in preparation of an antifungal drug. Based on the fact that the compound as shown in the formula (I) can be used as a CCd1 and Mdr1 double-target inhibitor, the inhibition effect of the compound on candida albicans, candida auricula, candida glabrata, candida tropicalis, trichophyton rubrum and trichophyton indicus when the compound is combined with azole drugs is further evaluated, and the result shows that the compound as shown in the formula (I) has no obvious antibacterial activity on various fungi, and can be used for preparing a medicine for treating various fungi. The drug resistance of CCd1 and Mdr1 overexpression drug-resistant fungi can be reversed, the activity of Candida albicans, Candida auricula, Candida glabrata, Candida tropicalis, Trichophyton rubrum and Trichophyton indicus can be synergistically inhibited when the drug is combined with azole drugs, the treatment dosage of the azole drugs is effectively reduced, and the drug toxicity is small. Therefore, the compound shown in the formula (I) can improve the antifungal effect of azole drugs and reduce the drug resistance of the azole drugs.

The invention discloses radix notoginseng stem and leaf rare ginsenoside as well as a preparation method and application thereof, and belongs to the technical field of ginsenoside. The radix notoginseng stem and leaf rare ginsenoside comprises Rk3, Rh4, S-Rg3, R-Rg3, Rk1 and Rg5. The radix notoginseng stem and leaf rare ginsenoside can be used for preparing radix notoginseng stem and leaf rare ginsenoside. The preparation method comprises the following steps: mixing the pseudo-ginseng stem and leaf extract with an acetic acid aqueous solution, reacting at 105-120 DEG C for 10-40 minutes, and drying; in the preparation process, macroporous resin purification is not carried out. According to the scheme, part of chemical substances in the panax notoginseng stem and leaf extract can be rapidly converted at a low temperature, new active substances Rh4, S-Rg3, R-Rg3, Rk1 and Rg5 with high purity are obtained at the same time, and the obtained panax notoginseng stem and leaf rare ginsenoside can effectively inhibit propionibacterium acnes, burkholderia cepacia and malassezia furfur.

The invention relates to lactobacillus gasseri FMTA1121E with an effect of regulating a vaginal micro-ecological environment and application of the lactobacillus gasseri FMTA1121E. The lactobacillus gasseri FMTA1121E is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1121E is CGMCC No.34962. The lactobacillus gasseri FMTA1121E can be metabolized to generate beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide so as to regulate the genital tract environment and improve the health degree; and the bacillus subtilis has excellent bacteriostasis and sterilization effects on various common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1121E strain can be applied to preparation of preparations for preventing and treating related genital tract diseases such as vaginitis.

A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;